Lipoatrophic diabetes and other related syndromes

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 1, 2003, Pages 61-77

  Oral, Elif Arioglu ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clinical abnormalities; Genetic basis genes; Insulin resistence; Leptin; Lipoatrophic diabetes; Other treatment

Indexed keywords

ACARBOSE; CCAAT ENHANCER BINDING PROTEIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SECRETAGOGUE; LAMIN A; LAMIN C; LEPTIN; METFORMIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ADOLESCENT; ADULT; CELL DIFFERENTIATION; CLINICAL FEATURE; CLINICAL TRIAL; COCKAYNE SYNDROME; CONGENITAL DISORDER OF GLYCOSYLATION; DYSLIPIDEMIA; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC RISK; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHIC DIABETES MELLITUS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; PRESCHOOL CHILD; PROGERIA; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SYNDROME; WERNER SYNDROME;

ANIMALS; DIABETES MELLITUS, LIPOATROPHIC; HUMANS; LIPODYSTROPHY;

EID: 0037363594     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021827520301     Document Type: Review

References (132)

1. Foster DW. The lipodystrophies and other rare disorders of the adipose tissue. In: Fauci AS et al., eds. Harrison's Principals of Internal Medicine. New York: McGraw-Hill, 1998:2209-2214.
2. Yura S, Ogawa Y, Sagawa N, Masuzaki H, Itoh H, Ebihara K, Aizawe-Abe M, Fujii S, Nakao K. Accelerated puberty and late-onset hypothalamic hypogonadism in female transgenic skinny mice overexpressing leptin. J Clin Invest 2000;105:749-755.
3. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inou G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105:1243-1252.
4. Waller EG, Wade AJ, Treasure J, Ward A, Leonard T, Powell-Tuck J. Physical measures of recovery from anorexia nervosa during hospitalised re-feeding. Eur J Clin Nutr 1996;50:165-170.
5. Horska A. Use of magnetic resonance in body composition studies: Applications to research on caloric restriction and exercise. Coll Antropol 1998;22:385-392.
6. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ, Spiegelman BM. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999;3:151-158.
7. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 1998;95:4333-4337.
8. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998;101:1-9.
9. Peterfy M, Phan J, Xu P, Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 2001;27:121-124.
10. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-416.
11. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000;105:271-278.
12. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-2010.
13. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-10703.
14. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892:146-154.
15. Taylor SI, Arioglu E, Syndromes associated with insulin resistance and acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998;9:419-439.
16. Kayikcioglu A, Akyurek M, Erk Y. Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr 1996;129:166-167.
17. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: Evidence for an immune pathogenesis. Br Med J 1980;280:1500-1503.
18. Murao S, Hirata K, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998;37:1031-1033.
19. Buyukgebiz A, Aydin A, Dundar B, Yorukoglu K. Localized lipoatrophy due to recombinant growth hormone therapy in a child with 6.7 kilobase gene deletion isolated growth hormone deficiency. J Pediatr Endocrinol Metab 1999;12:95-97.
20. Rees TD. Facial atrophy. Clin Plast Surg 1976;3:637-646.
21. Hodak E, David M, Sandbank M. Semicircular lipoatrophy - A pressure-induced lipoatrophy? Clin Exp Dermatol 1990;15:464-465.
22. Rongioletti F, Rebora A. Annular and semicircular lipoatrophies. Report of three cases and review of the literature. J Am Acad Dermatol 1989;20:433-436.
23. Berardinelli W. An undiagnosed endocrinometabolic syndrome: Report of two cases. Journal of Clinical Endocrinology 1954;14:193-204.
24. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr (Suppl) 1996;413:2-28.
25. Copeland KC, Nair KS, Kaplowitz PB, Robbins DC, Calles-Escandon J. Discordant metabolic actions of insulin in extreme lipodystrophy of childhood. J Clin Endocrinol Metab 1993;77:1240-1245.
26. Jaquet D, Khallouf E, Levy-Marchal C, Czemichow P. Extremely low values of serum leptin in children with congenital generalized lipoatrophy. Eur J Endocrinol 1999;140:107-109.
27. Pardini VC, Victoria IM, Rocha SM, Pieroni FB, Milagres G, Purisch S, Velho G. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998;83:503-508.
28. Oral EA, Simha V, Ruiz E, Andewett A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578.
29. Foss I, Trygstad O. Lipoatrophy produced in mice and rabbits by a fraction prepared from the urine from patients with congenital generalized lipodystrophy. Acta Endocrinol (Copenh) 1975;80:398-416.
30. Vigouroux C, Khallouf E, Bourut C, Robert JJ, de Kerdanet M, Tubiana-Rufi N, Faure S, Weissenbach J, Capeau J, Magre J. Genetic exclusion of 14 candidate genes in lipoatropic diabetes using linkage analysis in 10 consanguineous families. J Clin Endocrinol Metab 1997;82:3438-3444.
31. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magre J. Human peroxisome proliferator-activated receptor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998;47:490-492.
32. Silver K, Walston J, Plotnick L, Taylor SI, Kahn CR, Shuldiner AR. Molecular scanning of beta-3-adrenergic receptor gene in total congenital lipoatrophic diabetes mellitus. J Clin Endocrinol Metab 1997;82:3395-3398.
33. Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F, Kocak N, O'Rahilly S, Taylor SI, Patel SB, Bowcock AM, A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999;84:3390-3394.
34. Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr, Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Backy A, Verloes A, d'Abronzo FH, Seemanova E, Assan R, Baudic N, Bourut C, Czemichow P, Huet F, Grigorescu F, de Kerdanet M, Lacombe D, Labrune P, Lanza M, Loret H, Matsuda F, Navarro J, Nivelon-Chevalier A, Polak M, Robert JJ, Tric P, Tubiana-Rufi N, Vigouroux C, Weissenbach J, Savasta S, Maassen JA, Trygstad O, Bogalho P, Freitas P, Medina JL, Bonnicci F, Joffe BI, Loyson G, Panz VR, Raal FJ, O'Rahilly S, Stephenson T, Kahn CR, Lathrop M, Capeau J, BSCL Working Group. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001;28:365-370.
35. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002;31:21-23.
36. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR, Londos C. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 2001;98:6494-6499.
37. Pages C, Simon MF, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 2001;64:1-10.
38. Pages C, Simon M, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release(1). Prostaglandins 2001;64:1-10.
39. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids - Receptor revelations. Science 2001;294:1875-1878.
40. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-1945.
41. Rajab A, Heathcote K, Joshi S, Jeffery S, Patton M. Heterogeneity for congenital generalized lipodystrophy in seventeen patients from Oman. Am J Med Genet 2002;110:219-225.
42. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 1974;43:33-48.
43. Kobberling J, Willms B, Kattermann R, Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik 1975;29:111-120.
44. Wildermuth S, Spranger S, Spranger M, Raue F, Meinck HM. Kobberling-Dunnigan syndrome: A rare cause of generalized muscular hypertrophy. Muscle Nerve 1996;19:843-847.
45. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 1999;84:170-174.
46. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 2000;85:1776-1782.
47. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in canadian kindreds with dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000;9:109-112.
48. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN, Gregory S, O'Rahilly S, Trembath RC. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy [see comments]. Nat Genet 2000;24:153-156.
49. Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, Taylor SI, Lovett M, Bowcock AM. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the Globular C-terminal domain of lamin A/C. Am J Hum Genet 2000;66:1192-1198.
50. Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet 1998;18:292-295.
51. Jackson SN, Pinkney J, Bargiotta A, Veal CD, Howlett TA, McNally PG, Corral R, Johnson A, Trembath RC. A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q. Am J Hum Genet 1998;63:534-540.
52. Wilson KL. The nuclear envelope, muscular dystrophy and gene expression [In Process Citation], Trends Cell Biol 2000;10:125-129.
53. Heald R, McKeon F. Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell 1990;61:579-589.
54. Clements L, Manilal S, Love DR, Morris GE. Direct interaction between emerin and lamin A. Biochem Biophys Res Commun 2000;267:709-714.
55. Bonne G, Di Barletta MR, Vamous S, Becane HM, Hammouda EH, Merlini L, Muntoni F, Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, Toniolo D, Schwartz K. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-288.
56. Raffaele Di Barletta M, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, Romorini A, Voit T, Orstavik KH, Merlini L, Trevisan C, Biancalana V, Housmanowa-Petrusewicz I, Bione S, Ricotti R, Schwartz K, Bonne G, Toniolo D. Different Mutations in the LMNA gene cause autosomal dominant and autosomal recessive emery-dreifuss muscular dystrophy. Am J Hum Genet 2000;66:1407-1412.
57. Kitaguchi T, Matsubara S, Sato M, Miyamoto K, Hirai S, Schwartz K, Bonne G. A missense mutation in the exon 8 of lamin A/C gene in a Japanese case of autosomal dominant limb-girdle muscular dystrophy and cardiac conduction block. Neuromuscul Disord 2001;11:542-546.
58. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000:101:473-476.
59. Morris GE, Manilal S. Heart to heart: From nuclear proteins to emery-dreifuss muscular dystrophy. Hum Mol Genet 1999;8:1847-1851.
60. De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, Encoding Lamin A/C Nuclear-Envelope Proteins, Cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth Disorder Type 2) and mouse. Am J Hum Genet 2002;70:726-736.
61. Novelli G, Muchir A, Sangiuolo F, Helbling-LeClerc A, D'Apice MR, Massart C, Capon F, Sbraccia P, Federici M, Lauro R, Tudisco C, Pallotta R, Scarano G, Dallapiccola B, Merlini L, Bonne G. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002;71:426-431.
62. Lelliott CJ, Logie L, Sewter CP, Berger D, Jani P, Blows F, O'Rahilly S, Vidal-Puig A. Lamin expression in human adipose cells in relation to anatomical site and differentiation state. J Clin Endocrinol Metab 2002;87:728-734.
63. Holt I, Clements L, Manilal S, Brown SC, Morris GE. The R482Q lamin A/C mutation that causes lipodystrophy does not prevent nuclear targeting of lamin A in adipocytes or its interaction with emerin. Eur J Hum Genet 2001;9:204-208.
64. Barroso I, Gumell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
65. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002;87:408-411.
66. Yu CE, Oshima J, Wijsman EM, Nakura J, Miki T, Piussan C, Matthews S, Fu YH, Mulligan J, Martin GM, Schellenberg GD. Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative group. Am J Hum Genet 1997;60:330-341.
67. Henning KA, Li L, Iyer N, McDaniel LD, Reagan MS, Legerski R, Schultz RA, Stefanini M, Lehmann AR, Mayne LV. The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995;82:555-564.
68. Cotton RB, Keats TE, McCoy EE. Abnormal blood glucose regulation in Cockayne's syndrome. Pediatrics 1970:46:54-60.
69. Petersen MB, Brostrom K, Stibler H, Skovby F. Early manifestations of the carbohydrate-deficient glycoprotein syndrome. J Pediatr 1993;122:66-70.
70. Schwingshandl J, Mache CJ, Rath K, Borkenstein MH. SHORT syndrome and insulin resistance. Am J Med Genet 1993;47:907-909.
71. Aarskog D, Ose L, Pande H, Eide N. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am J Med Genet 1983;15:29-38.
72. Freidenberg GR, Cutler DL, Jones MC, Hall B, Mier RJ, Culler F, Jones KL, Lozzio C, Kaufmann S. Severe insulin resistance and diabetes mellitus in mandibuloacral dysplasia. Am J Dis Child 1992;146:93-99.
73. Cutler DL, Kaufmann S, Freidenberg GR. Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: A newly recognized form of partial lipodystrophy. J Clin Endocrinol Metab 1991;73:1056-1061.
74. Breslau-Siderius EJ, Toonstra J, Baart JA, Koppeschaar HP, Maassen JA, Beemer FA. Ectodermal dysplasia. lipoatrophy, diabetes mellitus, and amastia: A second case of the AREDYLD syndrome. Am J Med Genet 1992;44:374-377.
75. Simha V, Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 2002;87:776-785.
76. Van Maldergem L, Bachy A, Feldman D, Bouillon R, Maassen J, Dreyer M, Rey R, Holm C, Gillerot Y. Syndrome of lipoatrophic diabetes, vitamin D resistant rickets, and persistent Mullerian ducts in a Turkish boy born to consanguineous parents. Am J Med Genet 1996;64:506-513.
77. Davis TM, Holdright DR, Schulenberg WE, Turner RC, Joplin GF. Retinal pigment epithelial change and partial lipodystrophy. Postgrad Med J 1988;64:871-874.
78. Spranger S, Spranger M, Tasman AJ, Reith W, Voigtlander T, Voigtlander V. Barraquer-Simons syndrome (with sensorineural deafness): A contribution to the differential diagnosis of lipodystrophy syndromes. Am J Med Genet 1997;71:397-400.
79. Berger JR, Arioglu Oral E, Taylor SI. Familial lipodystrophy associated with neurodegeneration and congenital cataracts. Neurology 2002;58:43-47.
80. Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances: A case throwing new light on the action of insulin. Lancet 1946;1:724-731 and 773-775.
81. Hubler A, Abendroth K, Keiner T, Stocker W, Kauf E, Hein G, Stein G. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998;106:79-84.
82. Perrot H, Delaup JP, Chouvet B. [Barraquer and Simons lipodystrophy. Complement anomalies and cutaneous leukocytoclasic vasculitis]. Ann Dermatol Venereol 1987;114:1083-1091.
83. Biasi D, Caramaschi P, Carletto A, Bambara LM. A case of acquired partial lipodystrophy associated with localized scleroderma and undifferentiated connective tissue disease. Rheumatol Int 1999;19:75-76.
84. Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A. Partial lipodystrophy associated with juvenile dermatomyositis: Report of two cases. Pediatr Dermatol 1996;13:477-482.
85. Kavanagh GM, Colaco CB, Kennedy CT. Juvenile dermatomyositis associated with partial lipoatrophy. J Am Acad Dermatol 1993;28:348-351.
86. Sasaki T, Ono H, Nakajima H, Sugimoto J. Lipoatrophic diabetes. J Dermatol 1992;19:246-249.
87. Commens C, O'Neill P, Walker G. Dermatomyositis associated with multifocal lipoatrophy. J Am Acad Dermatol 1990;22:966-969.
88. Peters MS, Winkelmann RK. Localized lipoatrophy (atrophic connective tissue disease panniculitis). Arch Dermatol 1980;116:1363-1368.
89. Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, Peters DK. The complement abnormalities of lipodystrophy. N Engl J Med 1976;294:461-465.
90. McLean RH, Hoefnagel D. Partial lipodystrophy and familial C3 deficiency. Hum Hered 1980;30:149-154.
91. Fontaine M, Daveau M, Lebreton JP. Dumouchel L, Vannier JP, Godin M. Evidence that an autoantibody of IgG3 subclass against C3b discloses a C3 Nef activity in a pateint with partial lipodystrophy and glomerulonephritis. Ann Immunol (Paris) 1980;131C:39-53.
92. Jasin HE. Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia. J Rheumatol 1979;6:43-50.
93. Wakefield MA. The interrelationship between hypocomplementaemia, partial lipodystrophy and mesangiocapillary glomerulonephritis. Postgrad Med J 1976;52:651-652.
94. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids 1998;12:F51-F58.
95. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-1931.
96. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. Aids 1998;12:F37-F39.
97. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000;164:R7-R10.
98. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999;84:4274-4277.
99. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W, Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999;25:383-392.
100. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25:225-232.
101. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations. Aids 1999;13:2251-2260.
102. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. Aids 2000;14:37-49.
103. Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, DePaoli AM, Gorden P. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol and Metab 2002;87:3110-3117.
104. Brunzell JD, Shankle SW, Bethune JE. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann Intern Med 1968;69:501-516.
105. Bjornstad PG, Semb BK, Trygstad O, Seip M. Echocardiographic assessment of cardiac function and morphology in patients with generalised lipodystrophy. Eur J Pediatr 1985;144:355-359.
106. Rheuban KS, Blizzard RM, Parker MA, Carter T, Wilson T, Gutgesell HP. Hypertrophic cardiomyopathy in total lipodystrophy. J Pediatr 1986;109:301-302.
107. Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972;41:343-354.
108. Meyrier A. The patient with glomerulonephritis and lipodystrophy. Nephrol Dial Transplant 1997;12:226-227.
109. Casali RE, Resnick J, Goetz F, Simmons RL, Najarian JS, Kjellstrand C. Renal transplantation in a patient with lipoatrophic diabetes. A case report. Transplantation 1978;26:174-177.
110. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86.
111. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 2001;103:2225-2229.
112. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-1350.
113. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-870.
114. Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by leptin. J Biol Chem 1999;274:17541-17544.
115. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: Novel role of leptin. Proc Natl Acad Sci USA 1999;96:2327-2332.
116. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol 1998;29:495-501.
117. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Summer AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133:263-274.
118. Jequier E, Felber JP. Indirect calorimetry. Baillieres Clin Endocrinol Metab 1987;1:911-935.
119. Lillioja S, Bogardus C. Obesity and insulin resistance: Lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4:517-540.
120. Clark CM, Jr. The National Diabetes Education Program: Changing the way diabetes is treated. Ann Intern Med 1999;130:324-326.
121. Meyer L, Hadjadj S, Guerci B, Delbachian I, Ziegler O, Drouin P. Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion. Diabetes Metab 1998;24:544-546.
122. Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med 1988;108:334-340.
123. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:836-848.
124. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
125. lnzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metform in and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-872.
126. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185.
127. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 1997;100:2900-2908.
128. Bolan C, Oral EA, Gorden P, Taylor S, Leitman SF. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 2002;87:380-384.
129. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76.
130. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka W, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Frogvel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
131. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87:2395.
132. 2002 Online Mendelian Inheritence in Man. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at http://www.ncbi.nlm.nih.gov/OMIM.